

Grenoble, on 07th January 2013

Invitation to ETP-Nanomedicine stakeholders

Dear Sir/Madam, Dear Colleague,

Let me first introduce you to the European Technology Platform on Nanomedicine – ETP-N in short - , the only European think-tank on nanomedicine. ETP-N, an initiative set up by industry and the European Commission in 2005, is addressing the application of nanotechnology to achieve breakthroughs in healthcare. ETP-N promotes nanomedicine in Europe and lobbies for its development in medical technologies by proposing topics for upcoming calls. ETP-N supports its members in coordinating their joint research efforts and improving communication and networking amongst the members, as well as towards the European Commission and the European Member States. Our focus is on improving the translation of nanomedicine to industry and thus to the market, to bring nanomedicine related innovation to patients and to help our members as a result.

Europe is currently in a phase of active preparation and transition towards the new EU Framework Programme Horizon 2020, with its new tools and new priorities. It is the role of ETP-N to make sure that research, development and translation of nanomedicine will be recognised and actively supported under Horizon 2020. In addition we will help you and your organisation to adapt for translation and y to consider seriously what changes have to be made to successfully apply to future calls in the new system. It is likely that these changes will be reflected at national level too.

However, we would like to go much beyond this primary objective. In order to facilitate the emergence of a profitable nanomedicine sector in Europe, ETP-N wants to encourage the building of a continuous pipeline of discoveries, proofs of concept and finally nanomed products using your skills. This new supply chain originates in academia, then start-ups and SMEs before reaching the large companies with the capability of taking such nanomed concepts to the market.

We would like to invest a major effort in helping the practical side of <u>translation</u>. Translation means translation of expertise, competence but also of know-how and innovations up to early clinical trials. Behind this simple statement, a panel of practical actions is detailed in the attached Action Plan for 2013, including the major objective of creating the European **Nanomedicine Translation Hub**.

...

In the past 7 years; nanomedicine has been strongly supported by EC-FP7 thanks to ETP-N contribution. However, we would like to offer you much more. ETP-N is now evolving from a lobbying role to a more proactive role to bring you more visible benefits. Being a member of ETP-N will help you to make better strategic decisions, which will both enhance your career and hopefully provide funding for your organisation for applied research in the future.

The implementation of our new Action Plan 2013 promises a stronger commitment to our members, and is also inviting new members to join and help Europe to translate innovation into treatments to help patients. In order to make our efforts more efficient and more productive we are launching today a <u>recruitment</u> <u>campaign</u> focused on academia, hospitals, SMEs and large industries, that are part of the emerging nanohealth supply chain. This supply chain is important to patients and for the European economy, as well as European jobs.

We **invite you to join ETP-N** as a **new member** to reinforce our community, to make it stronger, and to ensure you get tangible benefits for your own business and science base. We know that together we can accelerate the development of nanomedicine for the benefit of patients.

You can register online and get all details regarding membership on our website:

http://www.etp-nanomedicine.eu/public/about/membership

We count on you to make nanomedicine a real hope for EU patients

Sincerely Yours,



Chairman of the Executive Board ETP-N

Attachments:

- ETP-N Action Plan 2013
- Benefits for ETP-N members